Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifestyle-induced weight loss and Liraglutide in the treatment of non-alcoholic steatohepatitis (NASH)
2016-002045-36Phase 2Terminated
- Sponsor
- University of Oxford
- Start
- Feb 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of liraglutide in metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by University of Oxford. Primary endpoint: Hepatic fat and inflammation by multiparametric MRI. Started Feb 2019; status: terminated.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2016-002045-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002045-36.